IVD China last week: Wantai, Mindray, MedicalSystem, Leadman, AmoyDx

Wantai Bio’s Wind ESG Rating Soars to AA, Ranking in the Top 7% of Listed Companies in A-Share and Hong Kong Markets

Recently, Wantai Bio achieved an upgrade to an AA rating in the prestigious Wind ESG Rating, ranking among the top 7% of A-share and Hong Kong-listed companies assessed. Within the Biotechnology III industry, the company secured second place out of 148 evaluated enterprises, with an overall score of 8.70 (industry average: 6.31). This authoritative recognition highlights Wantai Bio’s outstanding practices in environmental, social, and governance (ESG) performance, earning professional endorsement.

Mindray Group's Second Headquarters — Wuhan Facility Officially Inaugurated

After five years of dedicated construction, Mindray Medical has inaugurated its Wuhan facility as the group's second global headquarters. With a total investment of RMB 4.5 billion, the sprawling 620,000-square-meter complex is strategically positioned to drive innovation in minimally invasive surgery, orthopedics, and cardiovascular solutions – integrating R&D, manufacturing, and training across the entire value chain.

RMB 102 Million Budget! MedicalSystem Wins the Bid

China Government Procurement Network released the "Zhejiang Zhuohong Construction Project Management Co., Ltd. Announcement on the Bid-winning Results for Zhoushan Hospital's Centralized Supply Service Project of Clinical Testing Reagents and Supporting Consumables", with the original tender budget reaching a remarkable RMB 102 million.

According to the announcement, MedicalSystem successfully won the bid with a competitive offer of 21.88% (of the total budget). The supply period (contract term) is set for 3 years, with the contract validity commencing from the execution date. The agreement includes an annual performance evaluation mechanism to ensure service quality.

Leadman Plans to Acquire 70% Equity in Simcere Sanroad

Beijing Leadman Biochemistry Co.,Ltd. announced a proposed major asset restructuring plan. The Company has signed an "Investment Framework Agreement" with relevant transaction parties, planning to acquire a total of up to 70% equity in Beijing Simcere Sanroad Biological Products Co., Ltd. through cash payment. Upon completion of the transaction, Leadman will obtain control of Simcere Sanroad, which will then become its majority-owned subsidiary.

AmoyDx Semi-Annual Report: Core Diagnostic Reagents Maintain High Gross Margin of 90.72%

AmoyDx's 2025 Interim Report demonstrates a development trend characterized by "steady growth with structural optimization." The company achieved:

• Operating revenue of RMB 579 million, representing 6.69% year-on-year growth

• Net profit of 189 million yuan, marking 31.41% year-on-year increase

• Non-GAAP net profit growth of 39.97%, indicating significantly enhanced profitability

Key business highlights:

✓ Core diagnostic reagents business maintained an impressive 90.72% gross margin

✓ Obtained 2 new Class III medical device registrations

✓ Continued enrichment of product pipeline